Serum biomarkers for personalization of nanotherapeutics-based therapy in different tumor and organ microenvironments
Enhanced permeation and retention (EPR) effect, the mechanism by which nanotherapeutics accumulate in tumors, varies in patients based on differences in the tumor and organ microenvironment. Surrogate biomarkers for the EPR effect will aid in selecting patients who will accumulate higher amounts of...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Yokoi, Kenji [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2014transfer abstract |
|---|
| Schlagwörter: |
|---|
| Umfang: |
8 |
|---|
| Übergeordnetes Werk: |
Enthalten in: GW26-e0273 Relationship between thrombelastography test and routine platelet parameters in patients with acute coronary syndrome - Hao, Lijun ELSEVIER, 2015, an international journal providing a forum for original and pertinent contributions in cancer research, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:345 ; year:2014 ; number:1 ; day:1 ; month:04 ; pages:48-55 ; extent:8 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.canlet.2013.11.015 |
|---|
| Katalog-ID: |
ELV033892911 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV033892911 | ||
| 003 | DE-627 | ||
| 005 | 20230625195327.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180603s2014 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.canlet.2013.11.015 |2 doi | |
| 028 | 5 | 2 | |a GBVA2014010000019.pica |
| 035 | |a (DE-627)ELV033892911 | ||
| 035 | |a (ELSEVIER)S0304-3835(13)00825-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 570 | |
| 082 | 0 | 4 | |a 570 |q DE-600 |
| 082 | 0 | 4 | |a 610 |q VZ |
| 082 | 0 | 4 | |a 600 |a 690 |q VZ |
| 084 | |a 51.00 |2 bkl | ||
| 084 | |a 51.32 |2 bkl | ||
| 100 | 1 | |a Yokoi, Kenji |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Serum biomarkers for personalization of nanotherapeutics-based therapy in different tumor and organ microenvironments |
| 264 | 1 | |c 2014transfer abstract | |
| 300 | |a 8 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Enhanced permeation and retention (EPR) effect, the mechanism by which nanotherapeutics accumulate in tumors, varies in patients based on differences in the tumor and organ microenvironment. Surrogate biomarkers for the EPR effect will aid in selecting patients who will accumulate higher amounts of nanotherapeutics and show better therapeutic efficacy. Our data suggest that the differences in the vascular permeability and pegylated liposomal doxorubicin (PLD) accumulation are tumor type as well as organ-specific and significantly correlated with the relative ratio of MMP-9 to TIMP-1 in the circulation, supporting development of these molecules as biomarkers for the personalization of nanoparticle-based therapy. | ||
| 520 | |a Enhanced permeation and retention (EPR) effect, the mechanism by which nanotherapeutics accumulate in tumors, varies in patients based on differences in the tumor and organ microenvironment. Surrogate biomarkers for the EPR effect will aid in selecting patients who will accumulate higher amounts of nanotherapeutics and show better therapeutic efficacy. Our data suggest that the differences in the vascular permeability and pegylated liposomal doxorubicin (PLD) accumulation are tumor type as well as organ-specific and significantly correlated with the relative ratio of MMP-9 to TIMP-1 in the circulation, supporting development of these molecules as biomarkers for the personalization of nanoparticle-based therapy. | ||
| 650 | 7 | |a Nanotherapeutics |2 Elsevier | |
| 650 | 7 | |a Biomarker |2 Elsevier | |
| 650 | 7 | |a EPR effect |2 Elsevier | |
| 650 | 7 | |a PLD |2 Elsevier | |
| 650 | 7 | |a Transport oncophysics |2 Elsevier | |
| 700 | 1 | |a Tanei, Tomonori |4 oth | |
| 700 | 1 | |a Godin, Biana |4 oth | |
| 700 | 1 | |a van de Ven, Anne L. |4 oth | |
| 700 | 1 | |a Hanibuchi, Masaki |4 oth | |
| 700 | 1 | |a Matsunoki, Aika |4 oth | |
| 700 | 1 | |a Alexander, Jenolyn |4 oth | |
| 700 | 1 | |a Ferrari, Mauro |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Science |a Hao, Lijun ELSEVIER |t GW26-e0273 Relationship between thrombelastography test and routine platelet parameters in patients with acute coronary syndrome |d 2015 |d an international journal providing a forum for original and pertinent contributions in cancer research |g Amsterdam [u.a.] |w (DE-627)ELV013094742 |
| 773 | 1 | 8 | |g volume:345 |g year:2014 |g number:1 |g day:1 |g month:04 |g pages:48-55 |g extent:8 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.canlet.2013.11.015 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a GBV_ILN_11 | ||
| 912 | |a GBV_ILN_40 | ||
| 936 | b | k | |a 51.00 |j Werkstoffkunde: Allgemeines |q VZ |
| 936 | b | k | |a 51.32 |j Werkstoffmechanik |q VZ |
| 951 | |a AR | ||
| 952 | |d 345 |j 2014 |e 1 |b 1 |c 0401 |h 48-55 |g 8 | ||
| 953 | |2 045F |a 570 | ||
| author_variant |
k y ky |
|---|---|
| matchkey_str |
yokoikenjitaneitomonorigodinbianavandeve:2014----:euboakrfresnlztoonnteaetcbsdhrpidfeetuo |
| hierarchy_sort_str |
2014transfer abstract |
| bklnumber |
51.00 51.32 |
| publishDate |
2014 |
| allfields |
10.1016/j.canlet.2013.11.015 doi GBVA2014010000019.pica (DE-627)ELV033892911 (ELSEVIER)S0304-3835(13)00825-2 DE-627 ger DE-627 rakwb eng 570 570 DE-600 610 VZ 600 690 VZ 51.00 bkl 51.32 bkl Yokoi, Kenji verfasserin aut Serum biomarkers for personalization of nanotherapeutics-based therapy in different tumor and organ microenvironments 2014transfer abstract 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Enhanced permeation and retention (EPR) effect, the mechanism by which nanotherapeutics accumulate in tumors, varies in patients based on differences in the tumor and organ microenvironment. Surrogate biomarkers for the EPR effect will aid in selecting patients who will accumulate higher amounts of nanotherapeutics and show better therapeutic efficacy. Our data suggest that the differences in the vascular permeability and pegylated liposomal doxorubicin (PLD) accumulation are tumor type as well as organ-specific and significantly correlated with the relative ratio of MMP-9 to TIMP-1 in the circulation, supporting development of these molecules as biomarkers for the personalization of nanoparticle-based therapy. Enhanced permeation and retention (EPR) effect, the mechanism by which nanotherapeutics accumulate in tumors, varies in patients based on differences in the tumor and organ microenvironment. Surrogate biomarkers for the EPR effect will aid in selecting patients who will accumulate higher amounts of nanotherapeutics and show better therapeutic efficacy. Our data suggest that the differences in the vascular permeability and pegylated liposomal doxorubicin (PLD) accumulation are tumor type as well as organ-specific and significantly correlated with the relative ratio of MMP-9 to TIMP-1 in the circulation, supporting development of these molecules as biomarkers for the personalization of nanoparticle-based therapy. Nanotherapeutics Elsevier Biomarker Elsevier EPR effect Elsevier PLD Elsevier Transport oncophysics Elsevier Tanei, Tomonori oth Godin, Biana oth van de Ven, Anne L. oth Hanibuchi, Masaki oth Matsunoki, Aika oth Alexander, Jenolyn oth Ferrari, Mauro oth Enthalten in Elsevier Science Hao, Lijun ELSEVIER GW26-e0273 Relationship between thrombelastography test and routine platelet parameters in patients with acute coronary syndrome 2015 an international journal providing a forum for original and pertinent contributions in cancer research Amsterdam [u.a.] (DE-627)ELV013094742 volume:345 year:2014 number:1 day:1 month:04 pages:48-55 extent:8 https://doi.org/10.1016/j.canlet.2013.11.015 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_11 GBV_ILN_40 51.00 Werkstoffkunde: Allgemeines VZ 51.32 Werkstoffmechanik VZ AR 345 2014 1 1 0401 48-55 8 045F 570 |
| spelling |
10.1016/j.canlet.2013.11.015 doi GBVA2014010000019.pica (DE-627)ELV033892911 (ELSEVIER)S0304-3835(13)00825-2 DE-627 ger DE-627 rakwb eng 570 570 DE-600 610 VZ 600 690 VZ 51.00 bkl 51.32 bkl Yokoi, Kenji verfasserin aut Serum biomarkers for personalization of nanotherapeutics-based therapy in different tumor and organ microenvironments 2014transfer abstract 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Enhanced permeation and retention (EPR) effect, the mechanism by which nanotherapeutics accumulate in tumors, varies in patients based on differences in the tumor and organ microenvironment. Surrogate biomarkers for the EPR effect will aid in selecting patients who will accumulate higher amounts of nanotherapeutics and show better therapeutic efficacy. Our data suggest that the differences in the vascular permeability and pegylated liposomal doxorubicin (PLD) accumulation are tumor type as well as organ-specific and significantly correlated with the relative ratio of MMP-9 to TIMP-1 in the circulation, supporting development of these molecules as biomarkers for the personalization of nanoparticle-based therapy. Enhanced permeation and retention (EPR) effect, the mechanism by which nanotherapeutics accumulate in tumors, varies in patients based on differences in the tumor and organ microenvironment. Surrogate biomarkers for the EPR effect will aid in selecting patients who will accumulate higher amounts of nanotherapeutics and show better therapeutic efficacy. Our data suggest that the differences in the vascular permeability and pegylated liposomal doxorubicin (PLD) accumulation are tumor type as well as organ-specific and significantly correlated with the relative ratio of MMP-9 to TIMP-1 in the circulation, supporting development of these molecules as biomarkers for the personalization of nanoparticle-based therapy. Nanotherapeutics Elsevier Biomarker Elsevier EPR effect Elsevier PLD Elsevier Transport oncophysics Elsevier Tanei, Tomonori oth Godin, Biana oth van de Ven, Anne L. oth Hanibuchi, Masaki oth Matsunoki, Aika oth Alexander, Jenolyn oth Ferrari, Mauro oth Enthalten in Elsevier Science Hao, Lijun ELSEVIER GW26-e0273 Relationship between thrombelastography test and routine platelet parameters in patients with acute coronary syndrome 2015 an international journal providing a forum for original and pertinent contributions in cancer research Amsterdam [u.a.] (DE-627)ELV013094742 volume:345 year:2014 number:1 day:1 month:04 pages:48-55 extent:8 https://doi.org/10.1016/j.canlet.2013.11.015 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_11 GBV_ILN_40 51.00 Werkstoffkunde: Allgemeines VZ 51.32 Werkstoffmechanik VZ AR 345 2014 1 1 0401 48-55 8 045F 570 |
| allfields_unstemmed |
10.1016/j.canlet.2013.11.015 doi GBVA2014010000019.pica (DE-627)ELV033892911 (ELSEVIER)S0304-3835(13)00825-2 DE-627 ger DE-627 rakwb eng 570 570 DE-600 610 VZ 600 690 VZ 51.00 bkl 51.32 bkl Yokoi, Kenji verfasserin aut Serum biomarkers for personalization of nanotherapeutics-based therapy in different tumor and organ microenvironments 2014transfer abstract 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Enhanced permeation and retention (EPR) effect, the mechanism by which nanotherapeutics accumulate in tumors, varies in patients based on differences in the tumor and organ microenvironment. Surrogate biomarkers for the EPR effect will aid in selecting patients who will accumulate higher amounts of nanotherapeutics and show better therapeutic efficacy. Our data suggest that the differences in the vascular permeability and pegylated liposomal doxorubicin (PLD) accumulation are tumor type as well as organ-specific and significantly correlated with the relative ratio of MMP-9 to TIMP-1 in the circulation, supporting development of these molecules as biomarkers for the personalization of nanoparticle-based therapy. Enhanced permeation and retention (EPR) effect, the mechanism by which nanotherapeutics accumulate in tumors, varies in patients based on differences in the tumor and organ microenvironment. Surrogate biomarkers for the EPR effect will aid in selecting patients who will accumulate higher amounts of nanotherapeutics and show better therapeutic efficacy. Our data suggest that the differences in the vascular permeability and pegylated liposomal doxorubicin (PLD) accumulation are tumor type as well as organ-specific and significantly correlated with the relative ratio of MMP-9 to TIMP-1 in the circulation, supporting development of these molecules as biomarkers for the personalization of nanoparticle-based therapy. Nanotherapeutics Elsevier Biomarker Elsevier EPR effect Elsevier PLD Elsevier Transport oncophysics Elsevier Tanei, Tomonori oth Godin, Biana oth van de Ven, Anne L. oth Hanibuchi, Masaki oth Matsunoki, Aika oth Alexander, Jenolyn oth Ferrari, Mauro oth Enthalten in Elsevier Science Hao, Lijun ELSEVIER GW26-e0273 Relationship between thrombelastography test and routine platelet parameters in patients with acute coronary syndrome 2015 an international journal providing a forum for original and pertinent contributions in cancer research Amsterdam [u.a.] (DE-627)ELV013094742 volume:345 year:2014 number:1 day:1 month:04 pages:48-55 extent:8 https://doi.org/10.1016/j.canlet.2013.11.015 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_11 GBV_ILN_40 51.00 Werkstoffkunde: Allgemeines VZ 51.32 Werkstoffmechanik VZ AR 345 2014 1 1 0401 48-55 8 045F 570 |
| allfieldsGer |
10.1016/j.canlet.2013.11.015 doi GBVA2014010000019.pica (DE-627)ELV033892911 (ELSEVIER)S0304-3835(13)00825-2 DE-627 ger DE-627 rakwb eng 570 570 DE-600 610 VZ 600 690 VZ 51.00 bkl 51.32 bkl Yokoi, Kenji verfasserin aut Serum biomarkers for personalization of nanotherapeutics-based therapy in different tumor and organ microenvironments 2014transfer abstract 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Enhanced permeation and retention (EPR) effect, the mechanism by which nanotherapeutics accumulate in tumors, varies in patients based on differences in the tumor and organ microenvironment. Surrogate biomarkers for the EPR effect will aid in selecting patients who will accumulate higher amounts of nanotherapeutics and show better therapeutic efficacy. Our data suggest that the differences in the vascular permeability and pegylated liposomal doxorubicin (PLD) accumulation are tumor type as well as organ-specific and significantly correlated with the relative ratio of MMP-9 to TIMP-1 in the circulation, supporting development of these molecules as biomarkers for the personalization of nanoparticle-based therapy. Enhanced permeation and retention (EPR) effect, the mechanism by which nanotherapeutics accumulate in tumors, varies in patients based on differences in the tumor and organ microenvironment. Surrogate biomarkers for the EPR effect will aid in selecting patients who will accumulate higher amounts of nanotherapeutics and show better therapeutic efficacy. Our data suggest that the differences in the vascular permeability and pegylated liposomal doxorubicin (PLD) accumulation are tumor type as well as organ-specific and significantly correlated with the relative ratio of MMP-9 to TIMP-1 in the circulation, supporting development of these molecules as biomarkers for the personalization of nanoparticle-based therapy. Nanotherapeutics Elsevier Biomarker Elsevier EPR effect Elsevier PLD Elsevier Transport oncophysics Elsevier Tanei, Tomonori oth Godin, Biana oth van de Ven, Anne L. oth Hanibuchi, Masaki oth Matsunoki, Aika oth Alexander, Jenolyn oth Ferrari, Mauro oth Enthalten in Elsevier Science Hao, Lijun ELSEVIER GW26-e0273 Relationship between thrombelastography test and routine platelet parameters in patients with acute coronary syndrome 2015 an international journal providing a forum for original and pertinent contributions in cancer research Amsterdam [u.a.] (DE-627)ELV013094742 volume:345 year:2014 number:1 day:1 month:04 pages:48-55 extent:8 https://doi.org/10.1016/j.canlet.2013.11.015 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_11 GBV_ILN_40 51.00 Werkstoffkunde: Allgemeines VZ 51.32 Werkstoffmechanik VZ AR 345 2014 1 1 0401 48-55 8 045F 570 |
| allfieldsSound |
10.1016/j.canlet.2013.11.015 doi GBVA2014010000019.pica (DE-627)ELV033892911 (ELSEVIER)S0304-3835(13)00825-2 DE-627 ger DE-627 rakwb eng 570 570 DE-600 610 VZ 600 690 VZ 51.00 bkl 51.32 bkl Yokoi, Kenji verfasserin aut Serum biomarkers for personalization of nanotherapeutics-based therapy in different tumor and organ microenvironments 2014transfer abstract 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Enhanced permeation and retention (EPR) effect, the mechanism by which nanotherapeutics accumulate in tumors, varies in patients based on differences in the tumor and organ microenvironment. Surrogate biomarkers for the EPR effect will aid in selecting patients who will accumulate higher amounts of nanotherapeutics and show better therapeutic efficacy. Our data suggest that the differences in the vascular permeability and pegylated liposomal doxorubicin (PLD) accumulation are tumor type as well as organ-specific and significantly correlated with the relative ratio of MMP-9 to TIMP-1 in the circulation, supporting development of these molecules as biomarkers for the personalization of nanoparticle-based therapy. Enhanced permeation and retention (EPR) effect, the mechanism by which nanotherapeutics accumulate in tumors, varies in patients based on differences in the tumor and organ microenvironment. Surrogate biomarkers for the EPR effect will aid in selecting patients who will accumulate higher amounts of nanotherapeutics and show better therapeutic efficacy. Our data suggest that the differences in the vascular permeability and pegylated liposomal doxorubicin (PLD) accumulation are tumor type as well as organ-specific and significantly correlated with the relative ratio of MMP-9 to TIMP-1 in the circulation, supporting development of these molecules as biomarkers for the personalization of nanoparticle-based therapy. Nanotherapeutics Elsevier Biomarker Elsevier EPR effect Elsevier PLD Elsevier Transport oncophysics Elsevier Tanei, Tomonori oth Godin, Biana oth van de Ven, Anne L. oth Hanibuchi, Masaki oth Matsunoki, Aika oth Alexander, Jenolyn oth Ferrari, Mauro oth Enthalten in Elsevier Science Hao, Lijun ELSEVIER GW26-e0273 Relationship between thrombelastography test and routine platelet parameters in patients with acute coronary syndrome 2015 an international journal providing a forum for original and pertinent contributions in cancer research Amsterdam [u.a.] (DE-627)ELV013094742 volume:345 year:2014 number:1 day:1 month:04 pages:48-55 extent:8 https://doi.org/10.1016/j.canlet.2013.11.015 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_11 GBV_ILN_40 51.00 Werkstoffkunde: Allgemeines VZ 51.32 Werkstoffmechanik VZ AR 345 2014 1 1 0401 48-55 8 045F 570 |
| language |
English |
| source |
Enthalten in GW26-e0273 Relationship between thrombelastography test and routine platelet parameters in patients with acute coronary syndrome Amsterdam [u.a.] volume:345 year:2014 number:1 day:1 month:04 pages:48-55 extent:8 |
| sourceStr |
Enthalten in GW26-e0273 Relationship between thrombelastography test and routine platelet parameters in patients with acute coronary syndrome Amsterdam [u.a.] volume:345 year:2014 number:1 day:1 month:04 pages:48-55 extent:8 |
| format_phy_str_mv |
Article |
| bklname |
Werkstoffkunde: Allgemeines Werkstoffmechanik |
| institution |
findex.gbv.de |
| topic_facet |
Nanotherapeutics Biomarker EPR effect PLD Transport oncophysics |
| dewey-raw |
570 |
| isfreeaccess_bool |
false |
| container_title |
GW26-e0273 Relationship between thrombelastography test and routine platelet parameters in patients with acute coronary syndrome |
| authorswithroles_txt_mv |
Yokoi, Kenji @@aut@@ Tanei, Tomonori @@oth@@ Godin, Biana @@oth@@ van de Ven, Anne L. @@oth@@ Hanibuchi, Masaki @@oth@@ Matsunoki, Aika @@oth@@ Alexander, Jenolyn @@oth@@ Ferrari, Mauro @@oth@@ |
| publishDateDaySort_date |
2014-01-01T00:00:00Z |
| hierarchy_top_id |
ELV013094742 |
| dewey-sort |
3570 |
| id |
ELV033892911 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV033892911</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625195327.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2014 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.canlet.2013.11.015</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2014010000019.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV033892911</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0304-3835(13)00825-2</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">570</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">600</subfield><subfield code="a">690</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">51.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">51.32</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Yokoi, Kenji</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Serum biomarkers for personalization of nanotherapeutics-based therapy in different tumor and organ microenvironments</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2014transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">8</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Enhanced permeation and retention (EPR) effect, the mechanism by which nanotherapeutics accumulate in tumors, varies in patients based on differences in the tumor and organ microenvironment. Surrogate biomarkers for the EPR effect will aid in selecting patients who will accumulate higher amounts of nanotherapeutics and show better therapeutic efficacy. Our data suggest that the differences in the vascular permeability and pegylated liposomal doxorubicin (PLD) accumulation are tumor type as well as organ-specific and significantly correlated with the relative ratio of MMP-9 to TIMP-1 in the circulation, supporting development of these molecules as biomarkers for the personalization of nanoparticle-based therapy.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Enhanced permeation and retention (EPR) effect, the mechanism by which nanotherapeutics accumulate in tumors, varies in patients based on differences in the tumor and organ microenvironment. Surrogate biomarkers for the EPR effect will aid in selecting patients who will accumulate higher amounts of nanotherapeutics and show better therapeutic efficacy. Our data suggest that the differences in the vascular permeability and pegylated liposomal doxorubicin (PLD) accumulation are tumor type as well as organ-specific and significantly correlated with the relative ratio of MMP-9 to TIMP-1 in the circulation, supporting development of these molecules as biomarkers for the personalization of nanoparticle-based therapy.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Nanotherapeutics</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Biomarker</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">EPR effect</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">PLD</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Transport oncophysics</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tanei, Tomonori</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Godin, Biana</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">van de Ven, Anne L.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hanibuchi, Masaki</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Matsunoki, Aika</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Alexander, Jenolyn</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ferrari, Mauro</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Hao, Lijun ELSEVIER</subfield><subfield code="t">GW26-e0273 Relationship between thrombelastography test and routine platelet parameters in patients with acute coronary syndrome</subfield><subfield code="d">2015</subfield><subfield code="d">an international journal providing a forum for original and pertinent contributions in cancer research</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV013094742</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:345</subfield><subfield code="g">year:2014</subfield><subfield code="g">number:1</subfield><subfield code="g">day:1</subfield><subfield code="g">month:04</subfield><subfield code="g">pages:48-55</subfield><subfield code="g">extent:8</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.canlet.2013.11.015</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">51.00</subfield><subfield code="j">Werkstoffkunde: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">51.32</subfield><subfield code="j">Werkstoffmechanik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">345</subfield><subfield code="j">2014</subfield><subfield code="e">1</subfield><subfield code="b">1</subfield><subfield code="c">0401</subfield><subfield code="h">48-55</subfield><subfield code="g">8</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">570</subfield></datafield></record></collection>
|
| author |
Yokoi, Kenji |
| spellingShingle |
Yokoi, Kenji ddc 570 ddc 610 ddc 600 bkl 51.00 bkl 51.32 Elsevier Nanotherapeutics Elsevier Biomarker Elsevier EPR effect Elsevier PLD Elsevier Transport oncophysics Serum biomarkers for personalization of nanotherapeutics-based therapy in different tumor and organ microenvironments |
| authorStr |
Yokoi, Kenji |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV013094742 |
| format |
electronic Article |
| dewey-ones |
570 - Life sciences; biology 610 - Medicine & health 600 - Technology 690 - Buildings |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
570 570 DE-600 610 VZ 600 690 VZ 51.00 bkl 51.32 bkl Serum biomarkers for personalization of nanotherapeutics-based therapy in different tumor and organ microenvironments Nanotherapeutics Elsevier Biomarker Elsevier EPR effect Elsevier PLD Elsevier Transport oncophysics Elsevier |
| topic |
ddc 570 ddc 610 ddc 600 bkl 51.00 bkl 51.32 Elsevier Nanotherapeutics Elsevier Biomarker Elsevier EPR effect Elsevier PLD Elsevier Transport oncophysics |
| topic_unstemmed |
ddc 570 ddc 610 ddc 600 bkl 51.00 bkl 51.32 Elsevier Nanotherapeutics Elsevier Biomarker Elsevier EPR effect Elsevier PLD Elsevier Transport oncophysics |
| topic_browse |
ddc 570 ddc 610 ddc 600 bkl 51.00 bkl 51.32 Elsevier Nanotherapeutics Elsevier Biomarker Elsevier EPR effect Elsevier PLD Elsevier Transport oncophysics |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
t t tt b g bg d v a l v dval dvalv m h mh a m am j a ja m f mf |
| hierarchy_parent_title |
GW26-e0273 Relationship between thrombelastography test and routine platelet parameters in patients with acute coronary syndrome |
| hierarchy_parent_id |
ELV013094742 |
| dewey-tens |
570 - Life sciences; biology 610 - Medicine & health 600 - Technology 690 - Building & construction |
| hierarchy_top_title |
GW26-e0273 Relationship between thrombelastography test and routine platelet parameters in patients with acute coronary syndrome |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV013094742 |
| title |
Serum biomarkers for personalization of nanotherapeutics-based therapy in different tumor and organ microenvironments |
| ctrlnum |
(DE-627)ELV033892911 (ELSEVIER)S0304-3835(13)00825-2 |
| title_full |
Serum biomarkers for personalization of nanotherapeutics-based therapy in different tumor and organ microenvironments |
| author_sort |
Yokoi, Kenji |
| journal |
GW26-e0273 Relationship between thrombelastography test and routine platelet parameters in patients with acute coronary syndrome |
| journalStr |
GW26-e0273 Relationship between thrombelastography test and routine platelet parameters in patients with acute coronary syndrome |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
500 - Science 600 - Technology |
| recordtype |
marc |
| publishDateSort |
2014 |
| contenttype_str_mv |
zzz |
| container_start_page |
48 |
| author_browse |
Yokoi, Kenji |
| container_volume |
345 |
| physical |
8 |
| class |
570 570 DE-600 610 VZ 600 690 VZ 51.00 bkl 51.32 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Yokoi, Kenji |
| doi_str_mv |
10.1016/j.canlet.2013.11.015 |
| dewey-full |
570 610 600 690 |
| title_sort |
serum biomarkers for personalization of nanotherapeutics-based therapy in different tumor and organ microenvironments |
| title_auth |
Serum biomarkers for personalization of nanotherapeutics-based therapy in different tumor and organ microenvironments |
| abstract |
Enhanced permeation and retention (EPR) effect, the mechanism by which nanotherapeutics accumulate in tumors, varies in patients based on differences in the tumor and organ microenvironment. Surrogate biomarkers for the EPR effect will aid in selecting patients who will accumulate higher amounts of nanotherapeutics and show better therapeutic efficacy. Our data suggest that the differences in the vascular permeability and pegylated liposomal doxorubicin (PLD) accumulation are tumor type as well as organ-specific and significantly correlated with the relative ratio of MMP-9 to TIMP-1 in the circulation, supporting development of these molecules as biomarkers for the personalization of nanoparticle-based therapy. |
| abstractGer |
Enhanced permeation and retention (EPR) effect, the mechanism by which nanotherapeutics accumulate in tumors, varies in patients based on differences in the tumor and organ microenvironment. Surrogate biomarkers for the EPR effect will aid in selecting patients who will accumulate higher amounts of nanotherapeutics and show better therapeutic efficacy. Our data suggest that the differences in the vascular permeability and pegylated liposomal doxorubicin (PLD) accumulation are tumor type as well as organ-specific and significantly correlated with the relative ratio of MMP-9 to TIMP-1 in the circulation, supporting development of these molecules as biomarkers for the personalization of nanoparticle-based therapy. |
| abstract_unstemmed |
Enhanced permeation and retention (EPR) effect, the mechanism by which nanotherapeutics accumulate in tumors, varies in patients based on differences in the tumor and organ microenvironment. Surrogate biomarkers for the EPR effect will aid in selecting patients who will accumulate higher amounts of nanotherapeutics and show better therapeutic efficacy. Our data suggest that the differences in the vascular permeability and pegylated liposomal doxorubicin (PLD) accumulation are tumor type as well as organ-specific and significantly correlated with the relative ratio of MMP-9 to TIMP-1 in the circulation, supporting development of these molecules as biomarkers for the personalization of nanoparticle-based therapy. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_11 GBV_ILN_40 |
| container_issue |
1 |
| title_short |
Serum biomarkers for personalization of nanotherapeutics-based therapy in different tumor and organ microenvironments |
| url |
https://doi.org/10.1016/j.canlet.2013.11.015 |
| remote_bool |
true |
| author2 |
Tanei, Tomonori Godin, Biana van de Ven, Anne L. Hanibuchi, Masaki Matsunoki, Aika Alexander, Jenolyn Ferrari, Mauro |
| author2Str |
Tanei, Tomonori Godin, Biana van de Ven, Anne L. Hanibuchi, Masaki Matsunoki, Aika Alexander, Jenolyn Ferrari, Mauro |
| ppnlink |
ELV013094742 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth oth |
| doi_str |
10.1016/j.canlet.2013.11.015 |
| up_date |
2024-07-06T19:44:46.161Z |
| _version_ |
1803860140266356736 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV033892911</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625195327.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2014 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.canlet.2013.11.015</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2014010000019.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV033892911</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0304-3835(13)00825-2</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">570</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">600</subfield><subfield code="a">690</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">51.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">51.32</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Yokoi, Kenji</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Serum biomarkers for personalization of nanotherapeutics-based therapy in different tumor and organ microenvironments</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2014transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">8</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Enhanced permeation and retention (EPR) effect, the mechanism by which nanotherapeutics accumulate in tumors, varies in patients based on differences in the tumor and organ microenvironment. Surrogate biomarkers for the EPR effect will aid in selecting patients who will accumulate higher amounts of nanotherapeutics and show better therapeutic efficacy. Our data suggest that the differences in the vascular permeability and pegylated liposomal doxorubicin (PLD) accumulation are tumor type as well as organ-specific and significantly correlated with the relative ratio of MMP-9 to TIMP-1 in the circulation, supporting development of these molecules as biomarkers for the personalization of nanoparticle-based therapy.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Enhanced permeation and retention (EPR) effect, the mechanism by which nanotherapeutics accumulate in tumors, varies in patients based on differences in the tumor and organ microenvironment. Surrogate biomarkers for the EPR effect will aid in selecting patients who will accumulate higher amounts of nanotherapeutics and show better therapeutic efficacy. Our data suggest that the differences in the vascular permeability and pegylated liposomal doxorubicin (PLD) accumulation are tumor type as well as organ-specific and significantly correlated with the relative ratio of MMP-9 to TIMP-1 in the circulation, supporting development of these molecules as biomarkers for the personalization of nanoparticle-based therapy.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Nanotherapeutics</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Biomarker</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">EPR effect</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">PLD</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Transport oncophysics</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tanei, Tomonori</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Godin, Biana</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">van de Ven, Anne L.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hanibuchi, Masaki</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Matsunoki, Aika</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Alexander, Jenolyn</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ferrari, Mauro</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Hao, Lijun ELSEVIER</subfield><subfield code="t">GW26-e0273 Relationship between thrombelastography test and routine platelet parameters in patients with acute coronary syndrome</subfield><subfield code="d">2015</subfield><subfield code="d">an international journal providing a forum for original and pertinent contributions in cancer research</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV013094742</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:345</subfield><subfield code="g">year:2014</subfield><subfield code="g">number:1</subfield><subfield code="g">day:1</subfield><subfield code="g">month:04</subfield><subfield code="g">pages:48-55</subfield><subfield code="g">extent:8</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.canlet.2013.11.015</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">51.00</subfield><subfield code="j">Werkstoffkunde: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">51.32</subfield><subfield code="j">Werkstoffmechanik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">345</subfield><subfield code="j">2014</subfield><subfield code="e">1</subfield><subfield code="b">1</subfield><subfield code="c">0401</subfield><subfield code="h">48-55</subfield><subfield code="g">8</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">570</subfield></datafield></record></collection>
|
| score |
7.4016895 |